IP Library › Granted Patent US 7,226,591
Granted Patent B2
US 7,226,591 · App. 10/238,565 · Granted Jun 5, 2007

Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,226,591
App. No.
10/238,565
Granted
Jun 5, 2007
Kind
B2
Abstract

The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Claims (8)

1. A method of inhibiting Pancreatitis Associated Protein (PAP1) expression in mammalian cells, said method comprising contacting said cells with an antibody that binds to IL-22, thereby inhibiting said PAP1 expression by said cells.

2. The method of claim 1 , wherein the antibody is a monoclonal antibody.

3. The method of claim 1 , wherein the antibody is an antibody fragment.

4. The method of claim 3 , wherein the antibody fragment is a Fab, Fab′, F(ab′) 2 , Fv, or sFv fragment.

5. The method of claim 3 , wherein the antibody fragment is a single-chain antibody.

6. The method of claim 1 , wherein the antibody is a humanized antibody.

7. The method of claim 1 , wherein the antibody is a human antibody.

8. The method of claim 1 , wherein the cells are pancreatic cells.